OncoMatch/Clinical Trials/NCT05067348
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Is NCT05067348 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tocilizumab Injectable Product for myasthenia gravis, generalized.
Treatment: Tocilizumab Injectable Product — Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IV (MGFA)
MGFA Clinical Classification Class II, III, or IV.
Performance status
MGFA 2–4
Demographics
Prior therapy
Must have received: cholinesterase inhibitor
Cholinesterase inhibitor, with no dose increase within 4 weeks prior to randomization
Must have received: corticosteroids
Corticosteroids, with no dose increase within 4 weeks prior to randomization
Must have received: non-steroidal immunosuppressive therapy (azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A)
non-steroidal IST (including azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A), with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization
Cannot have received: rituximab (rituximab)
Received rituximab treatment in the past 6 months before randomization
Cannot have received: IL-6 inhibitor (tocilizumab)
Received tocilizumab ... within 3 months before randomization
Cannot have received: C5 inhibitor (eculizumab)
Received ... eculizumab treatment within 3 months before randomization
Cannot have received: IVIG
Received IVIG ... within 4 weeks before randomization
Cannot have received: plasma exchange
Received ... plasma exchange within 4 weeks before randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05067348 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior rituximab, IL-6 inhibitor, C5 inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA CLASS II or MGFA CLASS III or MGFA CLASS IV is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify